Experimental antibody shows promise in targeting leukemia cells
NCT ID NCT02860676
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tested the safety of an experimental drug called cirmtuzumab in 3 people with chronic lymphocytic leukemia (CLL) who had already received the drug before. Cirmtuzumab is a lab-made antibody that attaches to a protein called ROR1 found on CLL cells, aiming to block their growth while sparing healthy cells. The goal was to see if giving the drug for 6 to 12 months is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.